( respectively [2] Food and Drug Admin...)Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension,Health

, respectively
[2] Food and Drug Administration (FDA) and Committee for Medicinal Products for Human Use (CHMP)
[3] Ambulatory blood pressure is measured by a portable device worn by the patient over 24 hours at pre-determined intervals
Office blood pressure (systolic and diastolic) is measured when the patient is in the physician's office at pre-determined intervals
[4] Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor Blocker O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A, Hypertension. 2007;49:276-284.
[5] Angiotensin Converting Enzyme Inhibitor
[6] Uresin Y et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. European Society of Hypertension. 16th European Meeting on Hypertension. June 12-15, 2006; Madrid, Spain.

[i] Tekturna/Rasilez® are Novartis trademarks

For further information please contact

Nick Miles
Director Communications & Investor Relations
Speedel
Hirschgässlein 11
CH - 4051 Basel
Switzerland

T +41 (0) 61 206 40 00
D +41 (0) 61 206 40 14
F +41 (0) 61 206 40 01
M +41 (0) 79 446 25 21
E nick.miles@speedel.com
www.speedel.com

Frank LaSaracina
Managing Director
Speedel Pharmaceuticals Inc
1661 Route 22 West
P.O. Box 6532
Bridgewater, NJ 08807
United States of America

T +1 732 537 2290
F +1 732 537 2292
M +1 908 338 0501
E frank.lasaracina@speed
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
9. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
10. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting